Repozytorium UR

Infliximab in therapy of inflammatory bowels diseases

DSpace Repository

Show simple item record

dc.contributor.author Bar, Piotr
dc.contributor.author Galiniak, Sabina
dc.contributor.author Bartusik-Aebisher, Dorota
dc.contributor.author Filip, Rafał
dc.contributor.author Aebisher, David
dc.date.accessioned 2019-04-15T08:57:43Z
dc.date.available 2019-04-15T08:57:43Z
dc.date.issued 2019
dc.identifier.citation European Journal of Clinical and Experimental Medicine T. 17, z. 1 (2019), s. 79–82 pl_PL.UTF-8
dc.identifier.issn 2544-2406
dc.identifier.uri http://repozytorium.ur.edu.pl/handle/item/4527
dc.description Dorota Bartusik-Aebisher acknowledges support from the National Center of Science NCN (New drug delivery systems-MRI study, Grant OPUS-13 number 2017/25/B/ST4/02481). pl_PL.UTF-8
dc.description.abstract Introduction. Infliximab is a monoclonal antibody that acts against tumor necrosis factor TNF-α. The drug is used in the treatment of autoimmune diseases. Aim. This article reviewed the efficacy and safety of infliximab for the treatment in severe ulcerative colitis. This review included studies that evaluated the clinical use of infliximab. Material and methods. This meta-analysis was performed according to systematic literature search of three major bibliographic databases (Scopus, PubMed, and Cochran). Results. Infliximab has been approved by the US Food and Drug Administration (FDA) as a medicine to treat Leśniowski and Crohn’s disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. However, further trials are required to compare other parameters of efficacy such as the clinical response with infliximab. Conclusion. In patients suffering from Crohn’s disease or ulcerative colitis under infliximab maintenance therapy, sustained good trough levels are associated with: better response and remission rates, more mucosal healing and less loss of response. pl_PL.UTF-8
dc.language.iso eng pl_PL.UTF-8
dc.publisher Wydawnictwo Uniwersytetu Rzeszowskiego pl_PL.UTF-8
dc.rights Attribution-NonCommercial-NoDerivatives 4.0 Międzynarodowe *
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/ *
dc.subject infliximab pl_PL.UTF-8
dc.subject TNFα pl_PL.UTF-8
dc.subject ulcerative colitis pl_PL.UTF-8
dc.title Infliximab in therapy of inflammatory bowels diseases pl_PL.UTF-8
dc.type review pl_PL.UTF-8
dc.identifier.doi 10.15584/ejcem.2019.1.13
dc.identifier.eissn 2544-1361


Files in this item

The following license files are associated with this item:

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Międzynarodowe Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Międzynarodowe

Search DSpace


Browse

My Account

Statistics

Informacje